UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 33

Sortiert nach

Potent suppression of hydrophobic bile acids by aldafermin, an FGF19 analogue, across metabolic and cholestatic liver diseases

JHEP reports, 2021-06, Vol.3 (3), p.100255, Article 100255

2021

Link zum Volltext

Verfügbarkeit prüfen

A blood-based gene expression test for obstructive coronary artery disease tested in symptomatic nondiabetic patients referred for myocardial perfusion imaging the COMPASS study

Circulation. Cardiovascular genetics, 2013-04, Vol.6 (2), p.154

2013

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Nonalcoholic Steatohepatitis

Gastroenterology (New York, N.Y. 1943), 2021-01, Vol.160 (1), p.219-231.e1

2021

Link zum Volltext

Verfügbarkeit prüfen

The Commensal Microbe Veillonella as a Marker for Response to an FGF19 Analog in NASH

Hepatology (Baltimore, Md.), 2021-01, Vol.73 (1), p.126-143

2021

Link zum Volltext

Verfügbarkeit prüfen

Safety of regadenoson, an adenosine A2A receptor agonist for myocardial perfusion imaging, in mild asthma and moderate asthma patients: A randomized, double-blind, placebo-controlled trial

Journal of nuclear cardiology, 2008-05, Vol.15 (3), p.329-336

2008

Link zum Volltext

Verfügbarkeit prüfen

A randomized, double-blind, placebo-controlled trial of aldafermin in patients with NASH and compensated cirrhosis

Hepatology (Baltimore, Md.), 2024-03, Vol.79 (3), p.674-689

2024

Link zum Volltext

Verfügbarkeit prüfen

"Real-World" Comparison of Prasugrel With Ticagrelor in Patients With Acute Coronary Syndrome Treated With Percutaneous Coronary Intervention in the United States

Catheterization and cardiovascular interventions, 2016-10, Vol.88 (4), p.535-544

2016

Link zum Volltext

Verfügbarkeit prüfen

Eliminating atherogenesis in mice by switching off hepatic lipoprotein secretion

Circulation (New York, N.Y.), 2003-03, Vol.107 (9), p.1315-1321

2003

Link zum Volltext

Verfügbarkeit prüfen

Aldafermin in patients with non-alcoholic steatohepatitis (ALPINE 2/3): a randomised, double-blind, placebo-controlled, phase 2b trial

The lancet. Gastroenterology & hepatology, 2022-07, Vol.7 (7), p.603-616

2022

Link zum Volltext

Verfügbarkeit prüfen

Pharmacodynamics of a Novel Designer Natriuretic Peptide, CD-NP, in a First-in-Human Clinical Trial in Healthy Subjects

Journal of clinical pharmacology, 2009-06, Vol.49 (6), p.668-673

2009

Link zum Volltext

Verfügbarkeit prüfen

Real-world observations with prasugrel compared to clopidogrel in acute coronary syndrome patients treated with percutaneous coronary intervention in the United States

Current medical research and opinion, 2014-11, Vol.30 (11), p.2207-2216

2014

Link zum Volltext

Verfügbarkeit prüfen

Regadenoson, a selective A2A adenosine receptor agonist, causes dose-dependent increases in coronary blood flow velocity in humans

Journal of nuclear cardiology, 2007-07, Vol.14 (4), p.514-520

2007

Link zum Volltext

Verfügbarkeit prüfen

The RegEx trial: a randomized, double-blind, placebo- and active-controlled pilot study combining regadenoson, a selective A2A adenosine agonist, with low-level exercise, in patients undergoing myocardial perfusion imaging

Journal of nuclear cardiology, 2009-02, Vol.16 (1), p.63-72

2009

Link zum Volltext

Verfügbarkeit prüfen

Comparative resource utilization and costs for patients with acute coronary syndrome managed with percutaneous coronary intervention and treated with clopidogrel or prasugrel

American journal of health-system pharmacy, 2016-03, Vol.73 (6), p.395-403

2016

Link zum Volltext

Verfügbarkeit prüfen

The RegEx trial: a randomized, double-blind, placebo- and active-controlled pilot study combining regadenoson, a selective A(2A) adenosine agonist, with low-level exercise, in patients undergoing myocardial perfusion imaging

Journal of nuclear cardiology, 2009-01, Vol.16 (1), p.63-72

2009

Link zum Volltext

Verfügbarkeit prüfen

INITIAL EXPERIENCE WITH SUBCUTANEOUS INFUSION OF CENDERITIDE IN PATIENTS WITH CHRONIC HEART FAILURE

Journal of the American College of Cardiology, 2012-03, Vol.59 (13), p.E1037-E1037

2012

Link zum Volltext

Verfügbarkeit prüfen

Whole Blood Gene Expression Testing for Coronary Artery Disease in Nondiabetic Patients: Major Adverse Cardiovascular Events and Interventions in the PREDICT Trial

Journal of cardiovascular translational research, 2012-06, Vol.5 (3), p.366-374

2012

Link zum Volltext

Verfügbarkeit prüfen

A VALIDATED, PERIPHERAL BLOOD GENE EXPRESSION PATTERN CORRELATES WITH CORONARY ARTERIAL PLAQUE BURDEN BY QUANTITATIVE CORONARY ANGIOGRAPHY AND CORONARY ARTERY CALCIUM SCORING

Journal of the American College of Cardiology, 2011-04, Vol.57 (14), p.E1157-E1157

2011

Link zum Volltext

Verfügbarkeit prüfen

On the physiological importance of endoproteolysis of CAAX proteins: heart-specific RCE1 knockout mice develop a lethal cardiomyopathy

The Journal of biological chemistry, 2004-02, Vol.279 (6), p.4729-4736

2004

Link zum Volltext

Verfügbarkeit prüfen

MYOCARDIAL PERFUSION IMAGING PERFORMANCE IN THE PREDICT MULTI-CENTER TRIAL; GENDER SPECIFIC ANALYSIS AND COMPARISON WITH THE CORUS CAD GENE EXPRESSION SCORE

Journal of the American College of Cardiology, 2010-03, Vol.55 (10), p.A186.E1739-A186.E1739

2010

Link zum Volltext

Verfügbarkeit prüfen

The Commensal Microbe V eillonella as a Marker for Response to an FGF19 Analog in NASH

Hepatology (Baltimore, Md.), 2021-01, Vol.73 (1), p.126-143

2021

Link zum Volltext

Verfügbarkeit prüfen

Pharmacodynamics Pharmacodynamics of a Novel Designer Natriuretic Peptide, CD-NP, in a First-in-Human Clinical Trial in Healthy Subjects

Journal of clinical pharmacology, 2009-06, Vol.49 (6), p.668-673

2009

Link zum Volltext

Verfügbarkeit prüfen

Regadenoson, a selective A2A adenosine receptor agonist, causes dose-dependent increases in coronary blood flow velocity in humans

Journal of nuclear cardiology, 2007-07, Vol.14 (4), p.514-520

2007

Link zum Volltext

Verfügbarkeit prüfen

On the Physiological Importance of Endoproteolysis of CAAX Proteins

The Journal of biological chemistry, 2004-02, Vol.279 (6), p.4729-4736

2004

Link zum Volltext

Verfügbarkeit prüfen

Abstract 10649: Patient-Reported Outcome Labeling for Cardiovascular Drugs Approved in the United States: 2011-2017

Circulation (New York, N.Y.), 2018-11, Vol.138 (Suppl_1 Suppl 1), p.A10649-A10649

2018

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 33

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(32)
Mit Volltextzugriff
(28)

Publikationsform

Artikel
(33)

Sprache

Englisch
(33)
Japanisch
(7)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(18)
Science & Technology
(18)
Female
(12)
Humans
(12)
Male
(12)
Middle Aged
(10)
Aged
(8)
Cardiac & Cardiovascular Systems
(8)
Cardiovascular System & Cardiology
(8)
Adult
(7)
Treatment Outcome
(6)
Cardiology
(5)
Double-Blind Method
(5)
Gastroenterology & Hepatology
(5)
Adenosine
(4)
Animals
(4)
Cardiology And Cardiovascular Medicine
(4)
Cardiovascular
(4)
Internal Medicine
(4)
Acute Coronary Syndrome - Therapy
(3)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Potent suppression of hydrophobic bile acids by aldafermin, an FGF19 analogue, across metabolic and cholestatic liver diseases

A blood-based gene expression test for obstructive coronary artery disease tested in symptomatic nondiabetic patients referred for myocardial perfusion imaging the COMPASS study

Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Nonalcoholic Steatohepatitis

The Commensal Microbe Veillonella as a Marker for Response to an FGF19 Analog in NASH

Safety of regadenoson, an adenosine A2A receptor agonist for myocardial perfusion imaging, in mild asthma and moderate asthma patients: A randomized, double-blind, placebo-controlled trial

A randomized, double-blind, placebo-controlled trial of aldafermin in patients with NASH and compensated cirrhosis

"Real-World" Comparison of Prasugrel With Ticagrelor in Patients With Acute Coronary Syndrome Treated With Percutaneous Coronary Intervention in the United States

Eliminating atherogenesis in mice by switching off hepatic lipoprotein secretion

Aldafermin in patients with non-alcoholic steatohepatitis (ALPINE 2/3): a randomised, double-blind, placebo-controlled, phase 2b trial

Pharmacodynamics of a Novel Designer Natriuretic Peptide, CD-NP, in a First-in-Human Clinical Trial in Healthy Subjects

Real-world observations with prasugrel compared to clopidogrel in acute coronary syndrome patients treated with percutaneous coronary intervention in the United States

Regadenoson, a selective A2A adenosine receptor agonist, causes dose-dependent increases in coronary blood flow velocity in humans

The RegEx trial: a randomized, double-blind, placebo- and active-controlled pilot study combining regadenoson, a selective A2A adenosine agonist, with low-level exercise, in patients undergoing myocardial perfusion imaging

Comparative resource utilization and costs for patients with acute coronary syndrome managed with percutaneous coronary intervention and treated with clopidogrel or prasugrel

The RegEx trial: a randomized, double-blind, placebo- and active-controlled pilot study combining regadenoson, a selective A(2A) adenosine agonist, with low-level exercise, in patients undergoing myocardial perfusion imaging

INITIAL EXPERIENCE WITH SUBCUTANEOUS INFUSION OF CENDERITIDE IN PATIENTS WITH CHRONIC HEART FAILURE

Whole Blood Gene Expression Testing for Coronary Artery Disease in Nondiabetic Patients: Major Adverse Cardiovascular Events and Interventions in the PREDICT Trial

A VALIDATED, PERIPHERAL BLOOD GENE EXPRESSION PATTERN CORRELATES WITH CORONARY ARTERIAL PLAQUE BURDEN BY QUANTITATIVE CORONARY ANGIOGRAPHY AND CORONARY ARTERY CALCIUM SCORING

On the physiological importance of endoproteolysis of CAAX proteins: heart-specific RCE1 knockout mice develop a lethal cardiomyopathy

MYOCARDIAL PERFUSION IMAGING PERFORMANCE IN THE PREDICT MULTI-CENTER TRIAL; GENDER SPECIFIC ANALYSIS AND COMPARISON WITH THE CORUS CAD GENE EXPRESSION SCORE

The Commensal Microbe V eillonella as a Marker for Response to an FGF19 Analog in NASH

Pharmacodynamics Pharmacodynamics of a Novel Designer Natriuretic Peptide, CD-NP, in a First-in-Human Clinical Trial in Healthy Subjects

Regadenoson, a selective A2A adenosine receptor agonist, causes dose-dependent increases in coronary blood flow velocity in humans

On the Physiological Importance of Endoproteolysis of CAAX Proteins

Abstract 10649: Patient-Reported Outcome Labeling for Cardiovascular Drugs Approved in the United States: 2011-2017

Suchergebnisse filtern